TrialBMC cancer2017

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.

Seung Tae Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.